FDA Seeks Feedback on Fellowship and Traineeship Application Forms
Published Date: 10/28/2026
Notice
Summary
The FDA wants your thoughts on updating the application form for their Fellowship and Traineeship Programs. If you’re interested in these programs or know someone who might be, now’s the time to speak up! Comments are open until December 28, 2026, and there’s no cost to weigh in—just your ideas.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Voluntary online application option
You can apply to FDA fellowship and traineeship programs using a voluntary online application. FDA says the online option will reduce the time and cost of submitting written documentation and lessen the chance that applications are misrouted within the Agency.
Estimated application time and respondent counts
FDA estimates two application streams: the Medical Device Fellowship with 250 responses at 1 hour each (250 total hours) and the FDA Traineeship Program with 1,000 responses at 1 hour each (1,000 total hours), for a combined 1,250 hours annually. The collection is identified under OMB Control Number 0910-0780 as an extension.
Public comment opportunity by December 28, 2026
The FDA is accepting public comments on this proposed information collection through December 28, 2026; electronic comments are accepted via https://www.regulations.gov until 11:59 p.m. Eastern Time on that date. The notice includes instructions for confidential submissions and states comments filed in a timely manner will be placed in the public docket.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21913, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Color Additive Certification
The FDA is asking for approval to keep collecting info on color additives used in food, drugs, cosmetics, and medical devices. This helps ensure every batch meets safety and purity rules before hitting the market. If you’re involved in making or using these color additives, you can comment by November 27, 2026, but no new fees or big changes are expected.
Next: 2026-21915, Product Change-Priority Mail Express, Priority Mail, and USPS Ground Advantage Negotiated Service Agreements; Priority Mail and USPS Ground Advantage Negotiated Service Agreements
The Postal Service is updating its shipping deals by adding new contracts for Priority Mail Express, Priority Mail, and USPS Ground Advantage. These changes affect businesses using these services and could mean new pricing or options starting soon. The updates were officially filed in mid-October 2026 and are now under review to keep mail moving smoothly and competitively.